Avraham Gabay - 01 Jul 2026 Form 4 Insider Report for ORAMED PHARMACEUTICALS INC. (ORMP)

Reporting relationship: Chief Financial Officer
Issuer ticker: ORMP
Reported as of: 01 Jul 2026
Net transaction value: -$330,744
SEC form: 4
Accepted by SEC: 02 Jul 2026, 17:00:07 UTC
Prior SEC filing: 18 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Avraham Gabay

Key filing fact

Avraham Gabay filed Form 4 for ORAMED PHARMACEUTICALS INC. (ORMP) on 02 Jul 2026.

Key facts

This page summarizes Avraham Gabay's Form 4 filing for ORAMED PHARMACEUTICALS INC. (ORMP).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 02 Jul 2026, 17:00.

Change

Previous filing in this sequence was filed on 18 Mar 2026.
Current net transaction value: -$330,744.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001777328 Primary reporting owner

Gabay Avraham

Relationship: Chief Financial Officer
Address: 1185 AVENUE OF THE AMERICAS, THIRD FLOOR, NEW YORK
Signature: /s/ Avraham Gabay
Signature date: 02 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ORMP transaction

Common Stock

Sale

Transaction value: $330,744
Shares: -73,360
Change %: -9.8%
Price: $4.51
Shares after: 671,785
Date: 01 Jul 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.255 to $4.750, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.